Cancer immunotherapies using engineered autologous T cells have shown remarkable efficacy against some cancer. Dr. Holt’s team is engineering T cells to selectively deliver modified cytotoxic payloads and pro-drug activators for the purpose of enhanced tumour cell killing and overcoming immune resistance.
